BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

Impact · against what's priced in

The collaboration provides a catalyst for BioNTech by expanding the potential utility of Pumitamig into TNBC, a territory the market currently ignores. For Gilead, the news is largely redundant as the price already accounts for Trodelvy's expansion into first-line TNBC.

BNTX+0.30

Challenges what's priced in

The price assumes